Ada Health Partnership Opportunity Assessment - March 2026
Executive Summary
Total Opportunity: Ada Patient Finder can deliver $39.8M-$246.7M annually across J&J's specialty drug portfolio by identifying undiagnosed patients and navigating them to care.
Ada strength: Can identify skin symptoms AND screen for joint pain in psoriasis patients (9/10 surface ability)
Pitch Hook: "Tremfya is your $4B Stelara replacement, but 750,000+ Americans with psoriasis have undiagnosed joint pain. Ada can close the dermatology-rheumatology gap and deliver PsA patients at scale while you're expanding into Crohn's."
2. DARZALEX (daratumumab) - Multiple Myeloma
Annual Revenue$14.5B
Fit Score9/10
Revenue/Patient$135K
Market Opportunity
Market
Addressable Undiagnosed
Net Revenue/Patient
Ada Fee/Patient
Opportunity at 1%
Opportunity at 5%
USA
6,500
$135,000
$14,000
$910K
$4.55M
DACH
4,540
$90,000
$9,000
$408K
$2.04M
Rest of World
18,750
$90,000
$9,000
$1.69M
$8.44M
Why This Works
Blockbuster scale: $14.5B makes it a top-10 global drug
Diagnostic delay: 6-12 months from symptoms to diagnosis due to non-specific presentation (bone pain, fatigue, infections)
Expanding early: 2025 approval for smoldering MM shows J&J wants earlier diagnosis
Patent cliff approaching: Core patents expire 2030 - need to maximize patient capture before biosimilars
Ada fit: Can identify bone pain + fatigue + recurrent infections cluster (8/10 surface ability)
Pitch Hook: "Darzalex dominates multiple myeloma with $14.5B in sales, but 5,000-8,000 symptomatic Americans remain undiagnosed due to non-specific symptoms. Ada can identify the bone pain-fatigue-infection cluster and triage to hematology before your 2030 patent cliff."
Massive undiagnosed pool: 300K-950K Americans have TRD but don't know it (50% of depression undiagnosed, 30-55% develop resistance)
January 2025 monotherapy approval: Game-changer expanding eligible patient pool
Explosive growth: 61% YoY in 2024, $1.5B→$2.5B by 2030
Diagnostic delay: 165-197 days median between treatment switches - patients suffer while cycling through failed therapies
Ada fit: Can identify treatment history + severity (7/10, requires medication disclosure)
Pitch Hook: "300,000-950,000 Americans have treatment-resistant depression but don't know it. With your January 2025 monotherapy approval and 61% YoY growth, Ada can identify failed-treatment patterns and fast-track TRD patients to psychiatry before competitors capture them."
Pitch Hook: "Carvykti hit $1.9B as a blockbuster, but you need a pipeline. Ada finds multiple myeloma patients early, feeds them into Darzalex today, and creates 750-1,200 CAR-T candidates over 5 years at $465K each. That's pipeline building as a service."
50% DIE UNDIAGNOSED: Half of PAH patients never get proper diagnosis - this is life-saving
$30B Actelion acquisition: J&J's largest pharma deal - needs maximizing
Severe diagnostic delay: 2-3 years average, symptoms attributed to aging/deconditioning
Invasive diagnosis barrier: Requires right-heart catheterization - Ada can pre-screen for echo first
Perfect Ada fit: Dyspnea + fatigue + syncope + leg swelling cluster (9/10 surface ability)
Rare disease expertise: Shows J&J commitment to underserved populations
Pitch Hook: "You spent $30B on Actelion for PAH leadership, but half of PAH patients die undiagnosed. Ada can identify the dyspnea-fatigue-syncope cluster and save lives while protecting $3.6B in combined Uptravi/Opsumit revenue."
Strategic Recommendations
1. Lead with Tremfya
Why: Largest addressable pool (168K USA), highest total opportunity ($24M-120M), strategic urgency (Stelara replacement), and unique value proposition (closing dermatology-rheumatology gap for PsA).
2. Emphasize Darzalex + Carvykti Pipeline
Why: Highest revenue per patient, hematology dominance strategy, lifetime value narrative. "Find MM early → Darzalex today → Carvykti pipeline tomorrow."
3. Position Spravato for Rapid Growth
Why: 61% YoY growth, January 2025 monotherapy approval expansion, massive undiagnosed TRD pool, J&J neuroscience commitment ($15B CAPLYTA acquisition).
4. Uptravi/Opsumit - The Life-Saving Narrative
Why: 50% undiagnosed mortality rate, $30B acquisition to maximize, rare disease expertise, perfect symptom-based identification (vs. lab-based like CLL/nmCRPC).
5. Bundle Stelara → Tremfya Transition
Why: Use Patient Finder to defend Stelara market share against 85% biosimilar discounts, transition patients to Tremfya. "Find patients, J&J chooses IL-23 vs biosimilar based on insurance."
Implementation Roadmap
Phase
Timeline
Focus
Rationale
Phase 1
Months 1-6
Tremfya (PsA diagnostic gap)
Largest addressable, highest opportunity, strategic urgency
Phase 2
Months 4-9
Darzalex (MM early identification)
Highest per-patient value, expanding to smoldering MM
Phase 3
Months 7-12
Spravato (TRD identification)
Rapid growth, monotherapy expansion, large undiagnosed pool